Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 7/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145560 | 0.84 | NPY5R (0.35) | BDKRB1NPY5RHTR1APDCD1CD274 | |
| SCHEMBL4142908 | 0.82 | NPY5R (0.47) | ALKBH5FTOBDKRB1ATML3MBTL1 | |
| SCHEMBL4150130 | 0.80 | DPP7 (0.38) | ALKBH5FTOBDKRB1NPY5RHTR1A | |
| SCHEMBL4808441 | 0.79 | ATM (0.55) | ATML3MBTL1 | |
| SCHEMBL4154594 | 0.79 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL5951049 | 0.79 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL4148884 | 0.79 | CYP3A4 (0.41) | BDKRB1KCNH2 | |
| SCHEMBL4149466 | 0.78 | BDKRB1 (0.37) | ALKBH5FTOBDKRB1L3MBTL1NPY5R | |
| SCHEMBL4134116 | 0.78 | BDKRB1 (0.43) | ALKBH5BDKRB1L3MBTL1HTR1APDCD1 | |
| SCHEMBL4145157 | 0.77 | ALDH1A1 (0.41) | ALKBH5FTOBDKRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | ALKBH5 1697/4885FTO 2580/4885TRPV1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.